Close
Smartlab Europe
Inizio Ignite

Drug Research

Oncimmune and Biodesix Form Strategic Partnership to Unlock Full Potential of EarlyCDT Lung in US

Oncimmune Holdings plc ,a leading global immunodiagnostics group announces it has entered into an exclusive partnership agreement which it believes will unlock the full potential of EarlyCDT® Lung in the United States, bringing this lung cancer test to more...

Priorclave Launches New Autoclave Controller

All laboratory autoclaves and research sterilisers leaving the Priorclave design and manufacturing centre in the UK are now fitted with a new, technologically advanced controller. This is a significant up-grade; the new user interface features a hi-res digital display...

Artificial enzyme: Protein designed entirely from scratch functions in cells as a life-sustaining catalyst

A dawning field of research, artificial biology, is working toward creating a genuinely new organism. At Princeton, chemistry professor Michael Hecht and the researchers in his lab are designing and building proteins that can fold and mimic the chemical...

Elligo Health Research Launches Novel IntElligo Research Stack Clinical Technology

Elligo Health Research, an integrated research organization (IRO), announces the launch of its innovative IntElligo Research Stack™ clinical technology. This standards-based technology platform, which powers the System of Accelerated Research (SOAR™) model, will be launched this...

CALIXAR enters into collaboration with BIOTEM for the development of therapeutic antibodies against membrane targets

BIOTEM, a key player in the development of monoclonal antibodies of excellence, is pleased to announce the launch of a collaboration with CALIXAR, an innovative company specialized in the isolation and production of native and functional membrane proteins (MP)....

Why AI in Drug Discovery has Yet to Live Up to its Promise!

Being a life sciences researcher today involves being inundated with data from every direction. Every day, new studies are published, conferences held, and experiments conducted. Despite rumours the age of the ‘blockbuster’ drug might be over, we’re currently seeing record...

Development of biologics: The market requires short development times and high productivity

Biologics offer new therapy options for numerous diseases: They are already used to treat cancer and autoimmune diseases such as rheumatoid arthritis as useful alternatives to standard therapies. The extent of their market potential is revealed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »